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Abstract
Background: Hyperuricemia may be associated with an increased risk of coronary heart disease (CHD) mortality;
however, the results from prospective studies are conflicting. The objective of this study was to assess the
association between hyperuricemia and risk of CHD mortality by performing a meta-analysis.
Methods: Pubmed and Embase were searched for relevant prospective cohort studies published until July 2015.
Studies were included only if they reported data on CHD mortality related to hyperuricemia in a general
population. The pooled adjusted relative risk (RR) was calculated using a random-effects model.
Results: A total of 14 studies involving 341 389 adults were identified. Hyperuricemia was associated with an
increased risk of CHD mortality (RR: 1.14; 95 % CI: 1.06–1.23) and all-cause mortality (RR: 1.20; 95 % CI: 1.13–1.28).
For each increase of 1 mg/dl of serum uric acid (SUA), the overall risks of CHD and all-cause mortality increased by
20 and 9 %, respectively. According to the gender subgroup analyses, hyperuricemia increased the risk of CHD
mortality in women (RR: 1.47; 95 % CI: 1.21–1.73) compared to men (RR: 1.10; 95 % CI: 1.00–1.19). The risk of
all-cause mortality was greater in women.
Conclusions: Hyperuricemia may modestly increase the risk of CHD and all-cause mortality. Future research is
needed to determine whether urate–lowering therapy has beneficial effects for reducing CHD mortality.
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Background
Coronary heart disease (CHD) is a severe threat to
human health and has a high mortality rate. Many trad-
itional risk factors for CHD have been identified, such as
hyperlipidemia, hypertension, diabetes, and smoking.
Serum uric acid (SUA), the end product of purine
metabolism via an enzymatic reaction involving xanthine
oxidase, has also been correlated with CHD by several
studies [1–3]. However, because of controversial epide-
miologic findings and the lack of consistent evidence,
whether SUA is an independent and causal risk factor
for CHD remains unknown [4–10].
Several observational studies [4, 8, 11, 12] demonstrated
that elevated SUA has a predictive value for CHD risk and
that hyperuricemia may be an important causal factor for
CHD mortality. However, other studies [5, 6, 13–15]
contradict this. Many factors may contribute to the
conflicting conclusions. Subjectively, differences of the
studied populations, sample size, length of follow-up, and
methods of statistical analyses could influence the out-
come. Objectively, known risk factors, such as age, gender,
fat, weight index and other potential confounding factors,
under- or over -estimate the association between hyper-
uricemia and the risk of related disease.
However, regardless of whether hyperuricemia is a
causal risk factor for CHD mortality, several pathophysio-
logical mechanisms have been postulated for their rela-
tionship. SUA was considered to be a major antioxidant in
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humans with possible beneficial anti-atherosclerotic
effects in the early years. However, for patients with hyper-
uricemia, elevated SUA may have a more negative role by
stimulating oxidative stress and causing endothelial
dysfunction and inflammatory reactions [16]. Moreover,
the formation of oxygen free radicals and platelet adhesive-
ness are also induced by hyperuricemia [17]. These obser-
vations may explain some direct or indirect associations
between hyperuricemia and CHD.
A previous meta-analysis [18] suggested that hyperuri-
cemia is associated with the risk of CHD mortality and
that the association was stronger in women than men.
This study has practical implications regarding the
predication and prevention of CHD mortality and has
been cited frequently. However, we found that several of
the extracted data (RR or 95%CI) calculated in the meta-
analysis differed from the original studies. These errors
may alter the overall pooled results. In addition, several
relevant prospective studies have been published since
the previous meta-analysis was conducted. To accurately
and comprehensively estimate the influence of hyperu-
ricemia on CHD mortality in general populations, we
performed an updated meta-analysis.
Methods
Literature search
We performed a comprehensive literature search in
Pubmed and Embase for relevant prospective cohort
studies assessing the association between hyperuricemia
and CHD mortality. The search covered from the date
of inception until July 2015, and there was no language
restriction. The searched terms included hyperuricemia,
uric acid, coronary disease, coronary heart disease, cor-
onary artery disease, cardiac heart disease, cardiovascular
disease, death and mortality. In addition, the reference
lists of the selected articles were manually screened for
potential studies. Our meta-analysis was conducted
according to the checklist of Meta-analysis of Observa-
tional Studies in Epidemiology (MOOSE) [19].
Study selection
Studies that satisfied the following criteria were in-
cluded: 1) a prospective cohort study of adult subjects;
2) described the association between hyperuricemia and
CHD mortality; 3) an inception cohort involving adults
without CHD; and 4) reported adjusted risk estimates
for CHD mortality, such as relative risk (RR) or hazard
ratio (HR) with a 95 % confidence interval (95 % CI).
Data extraction and quality assessment
Two authors independently extracted data from all of
the included studies using a standardized Excel file. The
following data were extracted from each study: first
author, publication year, geographical location, sample
size, gender, age, duration of follow-up, definition of
hyperuricemia, outcome definition, adjusted risk esti-
mates regarding CHD and all-cause mortality, and con-
founding variables. The primary outcome was the risk
estimate for the association between hyperuricemia and
CHD mortality. The quality of selected studies was
evaluated using the Newcastle-Ottawa Scale [20]. The
quality score of the cohort studies was calculated based
on three components as follows: selection of the study
groups (0–4 points), comparability of study groups (0–2
points), and ascertainment of the interest outcome (0–3
points). The score ranges from 0 to 9 points, with a
higher score indicating better methodological quality.
Disagreements were resolved by consensus.
Statistical analysis
To standardize the unit of SUA of the included studies,
we converted it from μmol/L to mg/dl by dividing by
59.48. If a study reported the association between hyper-
uricemia and CHD mortality according to an age- or
SUA level-specific category, each was included in the
meta-analysis. A pooled estimate of the adjusted RR was
calculated using the DerSimonian and Laird random-
effects model. Heterogeneity across studies was evaluated
using the I2 statistic, which is a quantitative measure of
inconsistency across studies. A stratified analysis by gen-
der was conducted to assess the gender-related heterogen-
eity in the adjusted RR of CHD and all-cause mortality. If
evident heterogeneity was present, a sensitivity analysis
was conducted by omitting each study in turn to identify a
potential source. To explore the impact of the study
characteristics, such as gender, study region (Asia vs. non-
Asia), duration of follow-up (≤10 years vs. >10 years), and
sample size (<10,000 vs. >10,000), on the pooled RR, we
would conduct a multivariate meta-regression analysis.
But only the number of studies providing a same effect
size was more than ten can the analysis be done according
to the requirements of statistics recommended by the
Cochrane Collaboration. Publication bias was assessed
using both Begg’s test and Egger’s test. A two-tailed
p–value < 0.05 was considered statistically significant.
All statistical analyses were performed using Stata 12.0.
Results
Characteristics of the eligible studies
We retrieved 1373 articles with the initial literature
search. Two-hundred-eighty-six articles were excluded
because of duplicates. After screening the title or
abstract, 1028 studies were excluded, and the remaining
59 were further identified by reading the full-text.
According to the predefined inclusion criteria, 14 studies
[21–34] enrolling 341 389 participants were included in
the meta-analysis. Based on the reference lists of the
included studies, we retrieved six potential studies, but
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none met our inclusion criteria. Figure 1 shows the
detailed search strategy.
The characteristics of the included studies and their
participants are summarized in Table 1. Of the 14
included studies, four were performed in the United
States [21, 22, 29, 34], five in Europe [24, 26, 30, 31, 33]
and five in Asia [22, 25, 27, 28, 32]. All except one [24]
were written in English. The sample size of the studies
ranged from 1198 [26] to 90 393 [32] participants. The
duration of follow-up was between 5.4 [23] and 24.9 [27]
years. Of these studies, seven [22, 24, 26, 27, 32–34]
included both genders, five [23, 25, 28–30] included only
men, and two [21, 31] included only women. The defin-
ition of hyperuricemia ranged from 5.6 to 7.0 mg/dl in
men and from 5.4 to 7.0 mg/dl in women. Two studies
reported the results of RR between hyperuricemia and
CHD mortality based on the SUA level [23] and age [21]
subgroup. Ten studies [23–25, 27–31, 33, 34] reported
the association between the SUA level and CHD mortal-
ity based on different categories. Three [21, 22, 26]
presented the association the SUA level and CHD
mortality based on an increase of 1 mg/dl in each level,
and only one [32] represented it both ways. Nine studies
[21, 23–28, 32, 33] reported the association between
hyperuricemia and all-cause mortality. The majority of
studies defined CHD mortality using the International
Classification of Disease (ICD) codes from the hospital
records or death certificates. All of the selected studies
were assessed as high quality according to the NOS
scale. The median NOS score of the studies selected was
9 (range from 7 to 9).
CHD mortality
The pooled multivariate adjusted RR for CHD mortality
based on 11 studies [23–25, 27–34] was 1.14 (95 % CI:
1.06–1.23; Fig. 2). A slight heterogeneity between studies
was noted (I2 = 9.6 %, p >0.05). No significant publica-
tion bias was present according to Begg’s and Egger’s
test (both P values >0.05). The pooled adjusted RR for
CHD mortality was 1.10 (95 % CI: 1.00–1.19) among
men [23–25, 27–30, 32] and 1.47 (95 % CI: 1.21–1.73)
among women [24, 27, 31, 32]. There was no evident
heterogeneity between studies with respect to outcomes
(I2 = 0.0 %, 3.9 %).
For each increase of 1 mg/dl in the SUA level, the
pooled adjusted RR for CHD mortality based on four
studies [21, 22, 26, 32] was 1.20 (95 % CI: 1.10–1.29;
Fig. 3). Significant heterogeneity between studies was
observed (I2 = 53.3 %, p <0.05). Subsequently, a sensi-
tivity analysis was performed to identify the potential
source of heterogeneity. Exclusion of one study [32]
conducted by Chen et al. did not change the pooled
results (RR: 1.31; 95 % CI: 1.15–1.31), but no evi-
dence of heterogeneity was observed among the
remaining studies (I2 = 0.0 %, p = 0.53). Further exclu-
sion of any single study did not significantly alter the
overall combined RR (data not shown). The pooled
adjusted RR for each increase of 1 mg/dl in SUA was
1.18 (95 % CI: 1.08–1.28) among men [22, 26] and
1.31 (95 % CI: 1.18–1.43) among women [21, 22, 26].
No significant heterogeneity between studies was
noted with respect to outcomes (I2 = 0.0 % for both
genders).
All-cause mortality
Nine studies [21, 23–28, 32, 33] reported outcomes on
all-cause mortality. The pooled adjusted RR for all-cause
mortality based on seven studies [23–25, 27, 28, 32, 33]
was 1.20 (95 % CI: 1.13–1.28; Fig. 4). Significant he-
terogeneity between studies was observed (I2 = 63.5 %,
p <0.01). There was a significant publication bias accord-
ing to Begg’s test (p <0.05) and Egger’s test (p <0.01).
Because the number of studies was less than ten, a multi-
variate meta-regression was not performed. We only
performed a sensitivity analysis by excluding each study
individually to identify the potential source of heterogen-
eity. Exclusion of any single study did not significantly
alter the heterogeneity among the remaining studies. The
pooled adjusted RR for all-cause mortality was 1.15 (95 %
CI: 1.08–1.23) among men and 1.38 (95 % CI: 1.22–1.54)
among women. There was slight heterogeneity between
studies with respect to outcomes (I2 = 30.6 %, 32.5 %).
Fig. 1 Search strategy
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Table 1 Characteristics of studies included in the meta-analysis






Confounding factors Outcome definition NOS score
CHA-W [21] 1989 35–64 6797 white women in USA 11.5 Per 1 mg/dl
increase
Age, weight, smoking, DBP, cholesterol,
antihypertensive drugs, ECG abnormalities
ICD-8 codes on death certificates 4/2/3
NHANES-I [22] 2000 25–74 (48.1) 5962 (45.6) non-institutionalized
population in USA
16.4 M: 7.0; W: 5.6; Per
1 mg/dl increase
Age, race, BMI, cholesterol, smoking,
alcohol, hypertension, DM, diuretic use
ICD-9 codes on death certificates,
and/or a proxy interview
4/2/3
Tomita [23] 2000 25–60 49,413 male railroad workers
in Japan





2001 25–74 9710 (53.9) subjects in Belgia 10 M: 7.0; W: 5.4 M:age, DBP, educational level, smoking,
alcohol; W:age, cholesterol, SBP, BMI,
smoking, alcohol, DM
ICD-9 codes on hospital records 4/2/3
KMIC [25] 2004 44.6 ± 8.7 22,698 men in Korea 9 M: 7.0 Age, DM, hypertension, cholesterol, smoking Death certificates 4/2/3
Baibas [26] 2005 ≥25 1198 (42) adults in rural Greece 14 Per 1 mg/dl
increase
Age, village, educational level, weight,
smoking, alcohol, SBP, blood glucose,
cholesterol, triglycerides
ICD-9 codes on death certificates 4/2/3
Atomic bomb
Study [27]
2005 20–89 (48.6) 10,615 (36.4) Japanese atomic
bomb survivors
24.9 M: 7.0; W: 6.0 Age, BMI, smoking, alcohol, SBP, DM,
cholesterol, histories of hypertension,
kidney disease; malignant tumor;
estimated radiation dose





2006 49 ± 7 9125 men in Israel 23 M: 5.6 age, BMI, SBP, DM, smoking, LVH on ECG,
cholesterol
ICD-9 codes on death certificates
and hospital records
4/2/3
MRFIT [29] 2008 41–63 9105 men in USA 17 M: 7.0 Clinical center, age, BP, cholesterol,
triglyceride, smoking, family history of AMI,
aspirin and diuretic use, BMI
ICD-9 and 10 codes on
death certificates
4/2/3
VHMPP-M [30] 2008 41.6 83,863 Austrian men 13.6 M: 6.7 Age, BMI, BP, cholesterol, triglycerides,
glucose, smoking, year of examination
ICD-9 and 10 codes on death
certificates; autopsy records
4/2/3
VHMPP-W [31] 2008 62.3 ± 8.8 28,613 elderly Austrian women 15.2 W: 5.4 Age, BMI, BP, cholesterol, triglycerides,
glucose, smoking, occupational status,
year of examination





2009 51.5 ± 11.5 90,393 (46.3) adults in Taiwan 8.2 M and W: 7.0; Per
1 mg/dl increase
Age, BMI, cholesterol, triglycerides, DM,
hypertension, smoking, alcohol, sex
ICD-9 codes on death certificates 4/2/3
Puddu [33] 2014 35–74 2888 (44.1) adults from
Gubbio in Italy
13.5 M and W: 7.0 Age, gender, SBP, cholesterol, smoking, BMI,
blood glucose, e-GFR
ICD-9 codes on death certificates 4/2/3
NHANES-III
[34]
2015 45.3 11,009 (45.9) adults in USA 14.5 M and W: 6.3 Age, sex, race, BMI, SBP, smoking, HDL,
cholesterol, antihypertensive drug
ICD-10 codes on death
certificates
4/2/3
AMI acute myocardial infraction, BMI body mass index, BP blood pressure, CHA Chicago Heart Association, DM diabetes mellitus, DBP diastolic blood pressure, ECG electrocardiograph, e-GFR estimated-glomerular
filtration rate, HDL high-density lipoprotein, ICD international classification of disease, KMIC Korea Medical Insurance Corporation, LVH left ventricular hypertrophy, M men, MRFIT Multiple Risk factor Intervention Trial,













Based on this, the heterogeneity among the seven studies
may be related to gender.
For each increase of 1 mg/dl in the SUA level, the
pooled adjusted RR for all-cause mortality based on
three studies [21, 26, 32] was 1.09 (95 % CI: 1.02–1.17,
Fig. 5). Significant heterogeneity between studies was
observed (I2 = 59.4 %, p <0.05).
Meta-regression
A multivariate meta-regression was performed to
identify the predefined potential source of heterogen-
eity regarding CHD mortality. It demonstrated that
the heterogeneity across studies was related to gender
(p <0.05), rather than region, follow-up duration and
sample size.
Fig. 2 Forest plot of association between hyperuricemia and coronary heart disease mortality
Fig. 3 Forest plot of association between an increase of 1 mg/dl in serum uric acid level and coronary heart disease mortality
Zuo et al. BMC Cardiovascular Disorders  (2016) 16:207 Page 5 of 10
Discussion
Our updated meta-analysis demonstrates that hyperuri-
cemia is associated with a modest but statistically signifi-
cant increased risk of CHD and all-cause mortality. For
each increase of 1 mg/dl of SUA, the overall risks of
CHD and all-cause mortality increased by 20 and 9 %,
respectively. According to gender subgroup analyses,
hyperuricemia increased the risk of CHD mortality in
women (RR: 1.47; 95 % CI: 1.21–1.73) compared to men
(RR: 1.10; 95 % CI: 1.00–1.19). The risk of all-cause
mortality was greater for women.
Hyperuricemia has been correlated with hypertension,
hyperlipidemia, diabetes, metabolic syndrome and renal
disease, all of which could contribute to increased CHD
and all-cause mortality. Over the past few decades, rele-
vant studies [4, 5, 8, 13, 14, 21–37] have provided
Fig. 4 Forest plot of association between hyperuricemia and all-cause mortality
Fig. 5 Forest plot of association between an increase of 1 mg/dl in serum uric acid level and all-cause mortality
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conflicting evidence regarding the association between
hyperuricemia and CHD or all-cause mortality; there-
fore, whether hyperuricemia is an independent risk and
causal factor for CHD mortality remains unclear. This
phenomenon may be related to the differences in the
enrolled populations, definition of hyperuricemia, out-
comes studied, follow-up duration, sample size and
statistical adjustment.
To further investigate the association between hyper-
uricemia and CHD or all-cause mortality, Zhao et al.
[38] and Kim et al. [18] assessed it using a meta-analysis.
The study conducted by Zhao et al. showed that elevated
SUA increased the risk of cardiovascular mortality (RR:
1.37; 95 % CI 1.19–1.57) and all-cause mortality (RR:
1.24; 95 % CI: 1.09–1.42). The risk of cardiovascular
mortality was more pronounced in women (RR: 1.35;
95 % CI: 1.06–1.72). However, the association between
hyperuricemia and CHD mortality was not assessed
independently. Our meta-analysis suggests that hyperuri-
cemia is associated with all-cause mortality in both
genders (Fig. 4), whereas Zhao et al. only observed this
association for men (for women: RR 1.05; 95 % CI 0.79–
1.39). The explanation for such findings may be related
to the different inclusion criteria. Different from Zhao et
al., we chose an inception cohort involving adults with-
out CHD. In the other study, Kim et al. demonstrated
that hyperuricemia was associated with an increased risk
of CHD mortality (RR 1.16; 95 % CI 1.01–1.30), similar
to our findings. However, there were several mistakes
when the data (RR or 95%CI) were extracted from the
original studies (Additional file 1: Tables S1 and S2) [24,
26, 30, 31], which may have altered the pooled out-
comes. After correcting the mistake in their study, the
overall pooled outcomes were not significantly changed.
For the subgroup analysis, however, an increase of 1 mg/
dl in the SUA level was associated with CHD mortality
in both genders (Fig. 3), which is different from the pre-
vious meta-analysis [18] (RR 1.10, 95 % CI 0.96–1.24
among men; RR 1.17, 95 % CI 0.97–1.38 among women)
but similar to ours. Therefore, this difference is because
of the data extraction mistakes. Researchers found that
patients with angiographically confirmed CHD with
SUA levels in the upper quartile were five times more
likely to die than those in the lowest quartile [39]. The
risk of mortality increased by 26 % for each increase of
1 mg/dl in the SUA level and reflected the dose-
response relationship between the SUA levels and all-
cause mortality in patients with CHD. In a subsequent
study in 2015, von Lueder et al. [40] investigated the re-
lationship between SUA and clinical outcomes in sub-
jects with acute myocardial infarction complicated by
reduced left ventricular function or/and heart failure.
Their study showed that SUA strongly and independ-
ently predict adverse outcomes, and the finding of dose
dependent HR for all-cause and cardiovascular mortality
through survival curves according to quartiles of base-
line SUA. They concluded that the quantifcation of SUA
could improve clinical risk stratifcation of patients with
LV systolic dysfunction and/or HF following acute MI.
Similarly, our meta-analysis is also in conformity to the
results of the above two studies, but we suggests such a
dose-response relationship in the general population,
which may help to confirm the causal assiciation be-
tween HUA and CHD mortality from a different
perspective.
Although it remains unclear as to the role that ele-
vated SUA plays in CHD development and mortality, the
evidence suggests the following possible mechanisms.
First, several studies [41–45] suggested that hyperurice-
mia has a pathogenic role and predictive value in the
development of hypertension. Therefore, a causal link to
the development of hypertension is a plausible explan-
ation for the possible increased cardiovascular risk in
patients with hyperuricemia [46]. Second, increased SUA
levels may encourage lipid peroxidation and promote
the oxidation of low-density lipoprotein (LDL) choles-
terol [47], which may play a role in the development of
atherosclerosis [48] and would also explain its asso-
ciation with CHD [49]. Interestingly, because human
atherosclerosis plaques contain more UA than normal
artery walls, researchers propose that SUA may have a
direct role in the atherosclerosis process [50]. Third,
hyperuricemia may induce endothelial dysfunction,
which is predicted to promote the early development of
atherosclerosis and precede plaque formation [51]. The
deposition of urate crystals on the vessel wall could
cause an inflammatory reaction to then directly injure
the vascular intima and ultimately activating the platelet
and blood coagulation system. Finally, hyperuricemia
also promotes thrombosis [52, 53] and activates mono-
cyte chemotactic protein-1 [46], an important chemo-
kine in atherosclerosis.
Greater attention has been paid to whether urate-
lowing therapy improves cardiovascular outcomes. Hy-
peruricemia is frequently encountered in hypertensive
patients. Patients with hyperuricemia and hypertension
are associated with a 3- to 5-fold increase in CHD
compared to patients with normal SUA levels [54]. LIFE
is the first study to demonstrate that reducing the SUA
levels is associated with a reduction of cardiovascular
events in hypertensive patients [55]. Allopurinol, a xanthine
inhibitor, is frequently used in hyperuricemic patients to
reduce the SUA level. A meta-analysis of 10 studies showed
that allopurinol is associated with a small but significant
reduction in blood pressure [56]. High-dose allopurinol
therapy may prolong the time to chest pain during exercise
and improve endothelial dysfunction in patients with stable
angina pectoris [57]. These effects of allopurinol may be
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valuable for reducing future cardiovascular mortality.
Encouragingly, a prospective cohort study (n = 7135) dem-
onstrated that high-dose allopurinol treatment is associated
with a lower risk of cardiovascular events and mortality
[58]. Although previous studies have not yet provided direct
evidence that urate-lowering therapy reduces the risk of
CHD mortality in hyperuricemic patients, the studies dis-
cussed above provided some positive data. Hence, further
research is necessary.
Several limitations of this meta-analysis should be
acknowledged. First, although a multivariable adjust-
ment was conducted in most of the included studies,
confounding effects from other unadjusted risk factors
may exist. Notably, the majority of the considered stud-
ies were not adjusted for renal functionality or diuretics
or purine and fructose intake, which significantly influ-
ence the SUA level. In particular, renal functionality is
a main determinant of CHD and its mortality. So more
studies with subject-restriction to only those partici-
pants with normal eGFR are needed to conduct in the
future, only by this, the causal relationship between
hyperuricemia and risk of CHD mortality could be
accurately detected. Second, our results may be less
convincing because the SUA level may also be associ-
ated with other organ damage, such as heart failure or
IMT, or to the development of other relevant diseases,
such as type 2 diabetes [59]. Third, it’s important to
note that there was a significant publication bias with
regards to all-cause mortality. We attempted to minimize
publication bias by searching electronic databases with no
language restriction; however, because many researchers
didn’t focus on all-cause mortality and report it as a
primary or secondary outcome in related studies, and
studies with negative results and that are written in
non-English languages are less likely to be published,
publication bias still exists. Despite these limitations,
our study has several strengths. This meta-analysis is
based on large prospective cohort studies with a long
follow-up period in many different areas. Most of the
studies included in our meta-analysis reported the
adjusted RR. We assessed the quality of individual stud-
ies using the Newcastle-Ottawa Scale, which shows that
all of the studies were of high quality, making our
results more reliable. In addition, compared to the
previous meta-analysis [18], we included the latest
studies and corrected the data errors extracted from
the four papers (Additional file 1: Tables S1 and S2)
[24, 26, 30, 31] that we included. Because of this, our
statistical subgroup analyses suggested that regardless
of hyperuricemia or an increase of 1 mg/dl in the SUA
level, both are associated with CHD mortality in both
genders. Furthermore, we conducted a multivariate
meta-regression analysis on the log-transformed scale
of RR to explore the impact of the study characteristics.
Conclusions
In conclusion, our meta-analysis suggests that hyperuri-
cemia may modestly increase the risk of CHD and all-
cause mortality. Because there are safe and effective
methods to reduce SUA levels, future studies should
focus on the role of urate-lowering therapy for reducing
CHD mortality.
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association between hyperuricemia and CHD mortality. Table S2. The
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